Hepatorenal syndrome Medical Services in China

Hepatorenal syndrome (HRS) is a life-threatening functional renal failure that occurs in patients with advanced liver disease—most commonly decompensated cirrhosis or acute-on-chronic liver failure—without evidence of intrinsic kidney pathology. It is not caused by structural renal damage, obstruction, or nephrotoxic injury, but rather by profound systemic and splanchnic vasodilation, leading to intense renal vasoconstriction, reduced renal perfusion, and progressive decline in glomerular filtration rate (GFR). Two main types are recognized: Type 1 HRS, characterized by rapid deterioration in renal function (doubling of serum creatinine to >2.5 mg/dL or reduction in creatinine clearance by >50% to <20 mL/min within ≤2 weeks), and Type 2 HRS, marked by more gradual, stable but subnormal renal function (serum creatinine 1.5–2.5 mg/dL), often associated with refractory ascites. Pathogenesis centers on nitric oxide–mediated splanchnic arterial vasodilation, triggering activation of the renin-angiotensin-aldosterone system (RAAS), sympathetic nervous system, and endothelin pathways—culminating in intense renal cortical vasoconstriction and impaired sodium/water excretion. Epidemiologically, HRS develops in approximately 10–20% of hospitalized patients with cirrhosis and ascites over one year; among those with spontaneous bacterial peritonitis (SBP), incidence rises to 30–40%. Risk factors include severe portal hypertension, low mean arterial pressure (<80 mmHg), hyponatremia (<130 mmol/L), high Child-Pugh or MELD scores, recent large-volume paracentesis without albumin infusion, and infections—especially SBP. HRS profoundly impairs quality of life: patients experience debilitating fatigue, anorexia, confusion (hepatic encephalopathy), dyspnea from fluid overload, and profound anxiety related to prognosis and treatment uncertainty. Without intervention, median survival for Type 1 HRS is less than 2 weeks; even with pharmacologic therapy, 3-month mortality exceeds 50%. The condition imposes substantial psychosocial burden—limiting mobility, disrupting employment and family roles, and necessitating frequent hospitalizations. Early recognition and multidisciplinary management involving hepatology, nephrology, and critical care are essential. While liver transplantation remains the only definitive cure, timely diagnosis and bridge therapies (e.g., terlipressin + albumin) can stabilize renal function and improve transplant candidacy. Patient education, nutritional support, and palliative integration are vital components of holistic care in advanced disease.

Hepatorenal syndrome (HRS) is a functional, progressive renal failure that occurs in patients with advanced liver disease—most commonly decompensated cirrhosis—and/or acute-on-chronic liver failure (ACLF), in the absence of intrinsic renal pathology. It is not caused by structural kidney damage but rather by profound systemic and splanchnic vasodilation, leading to effective arterial hypovolemia, activation of endogenous vasoconstrictor systems (renin-angiotensin-aldosterone system, sympathetic nervous system, vasopressin), and intense renal vasoconstriction. This results in marked reduction in renal perfusion, glomerular filtration rate (GFR), and urine output, without significant proteinuria or active urinary sediment.

The primary underlying cause of HRS is severe hepatic dysfunction, particularly when associated with portal hypertension and ascites. Cirrhosis—most frequently due to chronic alcohol abuse, hepatitis B or C virus infection, non-alcoholic steatohepatitis (NASH), or autoimmune hepatitis—accounts for >90% of cases. Less common causes include fulminant hepatic failure, alcoholic hepatitis (especially severe forms meeting criteria for ACLF), and Budd-Chiari syndrome. Importantly, HRS is a diagnosis of exclusion: intrinsic renal diseases (e.g., acute tubular necrosis, glomerulonephritis, interstitial nephritis), prerenal azotemia from volume depletion, obstructive uropathy, and nephrotoxic drug exposure must be rigorously ruled out.

Triggers precipitating HRS in susceptible individuals include bacterial infections—particularly spontaneous bacterial peritonitis (SBP), which is the most common identifiable trigger—gastrointestinal bleeding, large-volume paracentesis without adequate albumin infusion (≥6–8 g albumin per liter of ascites removed), excessive diuretic use, and sepsis of any origin. These insults exacerbate systemic vasodilation and further impair renal perfusion pressure. Other triggers include worsening hepatic encephalopathy, hyponatremia (serum sodium <130 mmol/L), and rapid deterioration in synthetic liver function (e.g., falling albumin, rising INR, declining bilirubin clearance).

Established risk factors encompass both clinical and laboratory markers of advanced liver disease: presence of refractory ascites, serum creatinine ≥1.5 mg/dL, MELD score ≥15, hyponatremia (<130 mmol/L), low mean arterial pressure (<80 mmHg), high plasma renin activity, and elevated norepinephrine levels. Patients with Child-Pugh class C cirrhosis carry substantially higher risk than those with class A or B. Additional modifiable risk factors include prolonged use of nonsteroidal anti-inflammatory drugs (NSAIDs), angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), and inappropriate diuretic regimens. Recurrent episodes of SBP or other infections markedly increase cumulative risk.

No monogenic or strongly penetrant genetic factors have been identified for HRS. However, polymorphisms in genes regulating vascular tone and inflammation may confer susceptibility. Variants in the endothelial nitric oxide synthase (eNOS) gene (e.g., T-786C, Glu298Asp) are associated with enhanced nitric oxide production and exaggerated splanchnic vasodilation. Polymorphisms in the angiotensinogen (AGT) and angiotensin II type 1 receptor (AGTR1) genes may influence RAAS activation severity. Genome-wide association studies remain limited, and current evidence suggests HRS arises from complex gene–environment interactions rather than Mendelian inheritance. Family history is not a recognized clinical risk factor.

Environmental factors play a critical role in both disease progression and acute decompensation. Chronic alcohol exposure remains a leading environmental driver of cirrhosis—the principal substrate for HRS. Exposure to hepatotoxic agents (e.g., aflatoxin B1 in poorly stored grains, certain herbal remedies like pyrrolizidine alkaloids) contributes to liver injury in endemic regions. Poor sanitation and lack of access to vaccination increase hepatitis B and C transmission risk. Socioeconomic determinants—including delayed healthcare access, inconsistent medication adherence, malnutrition (especially protein-energy wasting), and unregulated use of nephrotoxic over-the-counter medications—significantly amplify risk. Hospital-acquired infections, invasive procedures (e.g., transjugular intrahepatic portosystemic shunt placement without prophylaxis), and iatrogenic volume depletion during management of ascites or variceal bleeding further represent key environmental contributors. Climate-related factors such as heat stress may exacerbate vasodilation and intravascular volume depletion in vulnerable patients. Prevention strategies therefore emphasize infection control, judicious diuretic use, albumin administration during paracentesis, avoidance of nephrotoxins, and early referral for liver transplantation evaluation.

Hepatorenal syndrome (HRS) is a life-threatening functional renal failure that occurs in patients with advanced liver disease—most commonly decompensated cirrhosis with ascites—and occasionally in acute-on-chronic liver failure or fulminant hepatic failure. It is not attributable to structural kidney injury, obstruction, or primary glomerular/tubulointerstitial disease; rather, it reflects profound systemic and splanchnic vasodilation leading to intense renal vasoconstriction, reduced renal perfusion, and progressive decline in glomerular filtration rate (GFR). HRS is classified into two types: Type 1 HRS is characterized by rapid deterioration in renal function (doubling of serum creatinine to >2.5 mg/dL or reduction in creatinine clearance by >50% to <20 mL/min within ≤2 weeks), often precipitated by bacterial infection (e.g., spontaneous bacterial peritonitis), large-volume paracentesis without plasma expansion, gastrointestinal bleeding, or excessive diuretic use. Type 2 HRS presents with more gradual, stable but subnormal renal function (serum creatinine 1.5–2.5 mg/dL), typically associated with refractory ascites and sodium retention, and carries a median survival of ~6 months without liver transplantation.

Early symptoms of HRS are frequently subtle and nonspecific, reflecting the underlying liver dysfunction rather than overt renal impairment. Patients may report increasing fatigue, mild confusion or sleep-wake cycle disturbances (early hepatic encephalopathy), worsening abdominal distension despite diuretic therapy, and diminished urine output (oliguria <500 mL/day) that is often overlooked or attributed to dehydration or over-diuresis. Nocturia may precede daytime oliguria due to impaired urinary concentrating ability secondary to altered renal hemodynamics and antidiuretic hormone dysregulation. Early laboratory clues include rising serum creatinine (often beginning at 1.2–1.4 mg/dL), declining estimated GFR, elevated blood urea nitrogen (BUN), and progressive hyponatremia (<130 mmol/L), which correlates strongly with severity and prognosis. Urinalysis typically shows bland sediment—absence of significant proteinuria (>500 mg/day), hematuria, cellular casts, or eosinophiluria—supporting a prerenal, non-inflammatory pathophysiology.

Typical symptoms emerge as renal dysfunction progresses. Oliguria becomes persistent and pronounced (<400 mL/day), sometimes progressing to anuria. Patients develop signs of volume overload—including worsening peripheral edema, tense ascites, and pulmonary congestion—despite low effective arterial blood volume, due to avid sodium and water retention mediated by activated renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system. Hypotension (systolic BP <90 mmHg) and tachycardia reflect systemic vasodilation and cardiac underfilling. Mental status changes may worsen due to combined effects of hyperammonemia, hyponatremia, and uremic encephalopathy. Pruritus, asterixis, and fetor hepaticus may intensify as hepatic synthetic and detoxification functions deteriorate.

Accompanying symptoms reflect multisystem decompensation. Gastrointestinal hemorrhage (e.g., variceal bleed) may be both a trigger and a consequence of coagulopathy and portal hypertension. Recurrent or persistent infections—particularly spontaneous bacterial peritonitis (SBP), urinary tract infection, or pneumonia—are common due to immune dysfunction (cirrhosis-associated immune deficiency syndrome, CAIDS) and serve as major precipitants of HRS-AKI. Patients often exhibit cachexia, muscle wasting, and hypoalbuminemia (<2.8 g/dL), contributing to edema and impaired drug metabolism. Endocrine manifestations include gynecomastia, testicular atrophy, and menstrual irregularities. Skin findings such as spider angiomas, palmar erythema, and leukonychia may be present. Laboratory hallmarks include elevated bilirubin (>5 mg/dL), prolonged INR (>2.0), thrombocytopenia (<100 × 10⁹/L), and markedly elevated plasma renin activity and norepinephrine levels.

Complications of HRS are severe and often fatal without intervention. Acute kidney injury (AKI) rapidly progresses to stage 3 AKI (serum creatinine ≥4.0 mg/dL or need for renal replacement therapy). Hepatic encephalopathy escalates to grade III–IV, with stupor or coma. Refractory ascites leads to spontaneous bacterial peritonitis, tense ascites-induced respiratory compromise, or umbilical hernia rupture. Electrolyte derangements—including severe hyponatremia (risk of seizures, coma), hyperkalemia (cardiac arrhythmias), and metabolic acidosis—further destabilize physiology. Sepsis and multiorgan dysfunction syndrome (MODS) frequently supervene. Mortality exceeds 50% at 1 month in untreated Type 1 HRS and approaches 90% at 6 months without liver transplantation.

Diagnosis relies on strict clinical criteria per the International Club of Ascites (ICA) 2015 revision. Essential features include: (1) diagnosis of cirrhosis with ascites; (2) serum creatinine >1.5 mg/dL; (3) no improvement in serum creatinine (<1.5 mg/dL) after at least 2 days of diuretic withdrawal and volume expansion with albumin (1 g/kg/day up to 100 g/day); (4) absence of shock, ongoing bacterial infection, nephrotoxic drug exposure (NSAIDs, aminoglycosides), or parenchymal kidney disease; and (5) absence of proteinuria (>500 mg/day), microhematuria (>50 RBC/hpf), or abnormal renal ultrasonography (e.g., hydronephrosis, cysts, or echogenicity suggesting chronic kidney disease). Confirmatory tests include fractional excretion of sodium (FeNa) <1% (typically <0.2%), low urinary sodium concentration (<10 mmol/L), and elevated plasma renin activity. Renal biopsy is contraindicated and unnecessary unless atypical features suggest intrinsic renal disease.

Differential diagnosis is critical to avoid misclassification. Prerenal azotemia from true hypovolemia (e.g., vomiting, diarrhea, over-diuresis) must be excluded by documented response to volume repletion. Acute tubular necrosis (ATN) is distinguished by higher FeNa (>2%), urinary sodium >40 mmol/L, muddy brown granular casts, and often a history of hypotension or nephrotoxin exposure. Glomerulonephritis presents with active urinary sediment, hematuria, proteinuria >1 g/day, and serologic markers (e.g., ANCA, anti-GBM, complement levels). Postrenal obstruction requires renal ultrasound to rule out hydronephrosis. Contrast-induced nephropathy follows iodinated contrast administration and usually peaks at 3–5 days. Hepatorenal syndrome must also be differentiated from other causes of AKI in cirrhosis, including sepsis-associated AKI (which may coexist but requires separate management) and acute fatty liver of pregnancy (in relevant demographics). Importantly, HRS-AKI should not be diagnosed in the setting of chronic kidney disease (eGFR <60 mL/min/1.73m² for >3 months) unless there is clear evidence of acute worsening superimposed on baseline.

Hepatorenal syndrome (HRS) is a life-threatening functional renal failure occurring in patients with advanced liver disease—most commonly decompensated cirrhosis or acute-on-chronic liver failure—without intrinsic kidney pathology. It is characterized by intense renal vasoconstriction, reduced glomerular filtration rate (GFR), sodium retention, and progressive azotemia, despite preserved renal histology. HRS is classified into two types: Type 1 (rapidly progressive, doubling of serum creatinine to >2.5 mg/dL within ≤2 weeks) and Type 2 (more indolent, with stable but elevated creatinine [1.5–2.5 mg/dL], often associated with refractory ascites). Early recognition and multidisciplinary intervention are critical, as untreated Type 1 HRS carries a median survival of <2 weeks.

Conservative treatment forms the cornerstone of initial management and focuses on optimizing systemic hemodynamics and minimizing nephrotoxic insults. Strict avoidance of nonsteroidal anti-inflammatory drugs (NSAIDs), diuretics (especially high-dose loop diuretics), and contrast media is mandatory. Volume expansion with albumin (1.0–1.5 g/kg on day 1, followed by 20–40 g/day) is essential—not only to counteract intravascular underfilling but also to improve effective arterial blood volume and attenuate neurohormonal activation (e.g., renin-angiotensin-aldosterone system and sympathetic nervous system). Paracentesis for large-volume ascites removal (>5 L) must be accompanied by intravenous albumin infusion (6–8 g/L of ascites removed) to prevent post-paracentesis circulatory dysfunction. Nutritional support—including adequate caloric intake (30–35 kcal/kg/day) and protein supplementation (1.2–1.5 g/kg/day, adjusted for hepatic encephalopathy)—is vital to mitigate catabolism and preserve renal perfusion. Close monitoring of serum electrolytes, creatinine, urine output, and mean arterial pressure guides fluid balance and prevents hyponatremia-induced cerebral edema or hypotension-induced renal hypoperfusion.

Pharmacologic therapy targets reversal of splanchnic vasodilation and subsequent renal vasoconstriction. Vasoconstrictors—particularly terlipressin—are first-line in most international guidelines (including EASL and AASLD) for Type 1 HRS. Terlipressin (initial dose 0.5–1 mg IV every 4–6 hours, titrated up to 2 mg every 4 hours based on creatinine response and systolic BP) improves renal perfusion by activating V1 receptors on splanchnic arterioles, thereby increasing systemic vascular resistance and cardiac preload. Its efficacy is significantly enhanced when combined with albumin. In regions where terlipressin is unavailable (e.g., the United States), norepinephrine (0.05–0.3 μg/kg/min IV) or midodrine plus octreotide (12.5–25 mg PO TID + 100 μg SC TID) may be used, though evidence supporting these regimens is less robust. Antibiotic prophylaxis (e.g., norfloxacin 400 mg daily or ciprofloxacin 500 mg daily) is indicated in patients with ascites and low ascitic fluid protein (<1.5 g/dL) to reduce spontaneous bacterial peritonitis—a major precipitant of HRS. Lactulose and rifaximin are employed to manage hepatic encephalopathy, which can exacerbate hemodynamic instability.

Surgical and procedural interventions are definitive but highly selective. Liver transplantation remains the only curative treatment for HRS, with 1-year post-transplant survival exceeding 70% in carefully selected candidates. Pre-transplant HRS increases perioperative risk but does not preclude transplantation; indeed, early listing is strongly recommended upon diagnosis. Transjugular intrahepatic portosystemic shunt (TIPS) may be considered in select patients with Type 2 HRS and well-preserved synthetic liver function (Child-Pugh A/B, MELD <18), as it reduces portal hypertension and improves renal hemodynamics in ~50% of cases. However, TIPS is contraindicated in overt hepatic encephalopathy, severe cardiopulmonary disease, or MELD ≥18 due to increased mortality risk. Renal replacement therapy (RRT)—including continuous venovenous hemofiltration (CVVH) or intermittent hemodialysis—is reserved for life-threatening complications (e.g., hyperkalemia, pulmonary edema, or uremic symptoms) and serves as a bridge to transplantation rather than definitive therapy. Extracorporeal albumin dialysis (e.g., molecular adsorbent recirculating system, MARS) has shown transient improvement in renal and hepatic parameters in small studies but lacks robust evidence for mortality benefit and is not routinely recommended outside clinical trials.

China offers distinct advantages in the comprehensive management of HRS. First, integrated hepatorenal care pathways—coordinated between hepatology, nephrology, transplant surgery, and critical care—are increasingly standardized across Tier-3 hospitals (e.g., Peking Union Medical College Hospital, Shanghai Ruijin Hospital), enabling rapid diagnostic workup and protocol-driven initiation of terlipressin-albumin therapy. Second, China’s National Medical Products Administration (NMPA) approved terlipressin in 2021, ensuring timely access without reliance on compassionate-use programs. Third, China leads globally in liver transplantation volume, performing over 6,000 procedures annually, with expanding use of extended-criteria donors and donation after circulatory death (DCD), shortening wait times. Fourth, innovative supportive therapies—including real-time point-of-care ultrasound-guided fluid assessment, AI-enhanced MELD scoring, and standardized nutritional rehabilitation protocols—are widely implemented in major centers. Finally, cost-effectiveness is notable: terlipressin and albumin regimens are substantially more affordable than in Western countries, and national health insurance covers ≥70% of transplant-related expenses for eligible patients.

Recovery and long-term prognosis hinge on sustained liver function improvement and prevention of recurrence. Patients achieving HRS reversal must undergo rigorous etiologic evaluation (e.g., viral hepatitis serology, autoimmune markers, genetic testing for Wilson disease or hemochromatosis) and receive targeted antiviral or immunomodulatory therapy where indicated. Lifelong abstinence from alcohol and avoidance of hepatotoxic agents are non-negotiable. Post-reversal, patients require quarterly nephrology follow-up including eGFR estimation (CKD-EPI equation), urinary NGAL or KIM-1 biomarkers (where available), and Doppler renal ultrasound to assess resistive index. Dietary sodium restriction (<2 g/day) and careful diuretic titration (spironolactone ± furosemide) are maintained under nephrology supervision. Vaccination against hepatitis A/B, influenza, and pneumococcus is strongly advised. Psychosocial support—including counseling and peer-led patient education groups—improves adherence and reduces hospital readmission. Importantly, even after apparent recovery, patients remain at lifelong risk for HRS recurrence; thus, any episode of infection, GI bleeding, or rapid diuresis warrants immediate nephrology consultation. With coordinated, guideline-concordant care—particularly in high-volume Chinese centers—the trajectory of HRS has shifted from uniformly fatal to potentially reversible, offering meaningful survival extension and improved quality of life.